Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study. The study will investigate the combination of its PD-L1 monoclonal antibody adebrelimab (SHR-1316) with concurrent chemotherapy for the treatment of locally advanced cervical cancer.
Adebrelimab, developed by Hengrui, was approved in China for the first-line treatment of extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy in March of the previous year. The drug is part of a growing field of immunotherapies targeting the PD-1/PD-L1 pathway, with a total of 17 PD-1/L1 inhibitors currently approved for marketing in China. Among these, only Akeso Bio’s cadonilimab, a bispecific antibody targeting both PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and Lee’s Pharma’s socazolimab are indicated for the treatment of cervical cancer.- Flcube.com
